Reference list

CD3/CD19 Depletion

Graft manipulation for prevention of graft-versus-host disease in paediatric non-malignant diseases.

Immune reconstitution after haploidential hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3/CD19 depleted grafts.

Positive immunomagnetic CD34(+) cell selection in haplo-identical transplants in beta-thalassemia patients: removal of platelets using an automated system.

Depletion of CD3 and CD19 positive cells from leukapheresis products with the CliniMACS device.

A proposal for antibody-based immunotherapy combined with haploidential stem cell transplantation for high-risk neuroblastoma.

Haploidential stem cell transplantation in pediatric patients with myelodysplastic syndrome.

Transplantation of CD3/CD19 depleted PBSC leading to viral clearance and no graft-versus-host disease in SCID.

Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidential related donors in pediatric leukemia patients.

CD3+/CD19-depleted grafts in HLA-matched allogeneic peripheral blood stem cell transplantation lead to early NK cell cytolytic responses and reduced inhibitory activity of NKG2A.

Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.

Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis.
Haplo-identical stem cell transplantation in children with relapsed neuroblastoma.
Bone Marrow Transplant. (2009) 43: S42.

Haplo-identical stem cell transplantation with CD3/CD19 depleted stem cells: analysis of activity and recovery of co-transfused NK cells.
Bone Marrow Transplant. (2009) 43: S43.

Haplo-identical allogeneic haematopoietic cell transplantation in adults using reduced-intensity conditioning and CD3/CD19-depleted grafts.

Allogeneic stem cell transplantation in Farber’s disease with bone involvement: long-lasting and substantial improvement.
Jarisch A, Soerensen J, Porto L, Kieslich M, Klingebiel T, Bader P.

Allogeneic haematopoietic stem cell transplantation in non-complete remission of acute myeloid leukaemia.
Dyshlevaya Z, Kurnikova E.

Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patient.

Lang P, Handgretinger R.

The history and future prospective of haplo-identical stem cell transplantation.
Handgretinger R, Lang P.

ISHAGE-based single-platform flowcytometric analysis for measurement of absolute viable T cells in fresh or cryopreserved products: CD34/CD133 selected or CD3/CD19 depleted stem cells, DLI and purified CD56+CD3− NK cells.


Feasibility and outcome of reduced intensity conditioning in haploidentical transplantation.
Handgretinger R, Chen X, Pfeiffer M, Mueller I, Feuchtinger T, Hale GA, Lang P.

Haploidentical stem cell transplantation in children: improved engraftment and immune recovery after depletion of T and B cells instead of positive selection of stem cells?

CD3/CD19 depleted peripheral stem cells for matched unrelated donor in combination with a reduced intensity regimen – a new option in children lacking a matched sibling donor?
Soerensen S, Becker M, Koehl U, Reinhard H, Klingebiel T, Bader P.

Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects.
Lang P, Pfeiffer M, Muller I, Ebinger M, Koscielniak E, Feuchtinger T, Foll J, Martin D, Handgretinger R.


Determination of residual T- and B-cell content after immunomagnetric depletion: proposal for flow cytometric analysis and results from 103 separations.
T- and B-cell depletion prior to transplantation of patients with refractory leukaemia from HLA-mismatched NK-alloreactive donors.


Feasibility of a clinical-scale CD3/CD19 depletion procedure to replace conventional CD34 positive selection.

Bone marrow transplantation after processing by gradients and negative immunomagnetic T- and B-cell selection to prevent GvHD without loss of engraftment potential.
Preijers F, Schattenberg A, Ruijs W, Trilsbeek C.

A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation.

Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for pediatric refractory hematological malignancies.

Mismatched family member donor transplantation for patients with refractory hematologic malignancies: Long-term follow-up of a prospective clinical trial.

Haploidentical transplantation for children with refractory hematologic malignancies.

A large-scale method for T cell depletion: towards graft engineering of mobilized peripheral blood stem cells.

CD3 Depletion

Effective CD3 T-cell depletion using the CliniMACS® System to produce peripheral blood progenitor cell products for haploidentical transplantation in 23 children and adults: the updated Lund experience.

Rapid and effective CD3 T-cell depletion with a magnetic cell sorting program to produce peripheral blood progenitor cell products for haploidentical transplantation in children and adults.

Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact. The CliniMACS® System components: Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer are manufactured and controlled under an ISO 13485 certified quality system. In Europe, the CliniMACS System components are available as CE-marked medical devices. In the USA, the CliniMACS System components including the CliniMACS Reagents are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). CliniMACS® MicroBeads are for research use only and not for use in humans. MACS and CliniMACS are registered trademarks or trademarks of Miltenyi Biotec GmbH. Copyright ©2011 Miltenyi Biotec GmbH. All rights reserved.